Announcements Trials
Browse Landscape

Phase

Phase 1 42Phase 2 23Phase 1/2 20Phase 3 12Phase EARLY_PHASE1 3Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 26Other hematologic neoplasm 23Breast 11Myeloid 5Plasma cell 4Classical hematology 3Sarcoma 2Other neoplasm 2Dermatologic 2Thoracic 1Head & Neck 1CNS 1

Conditions

Thymoma 1Thymic epithelial tumor 1Mediastinal Neoplasms 1

Interventions

Pemetrexed 23Carboplatin 21Cisplatin 20pembrolizumab 15Docetaxel 14Paclitaxel 10Gemcitabine 8Drug Therapy 7Bevacizumab 7Gefitinib 5Radiotherapy 4Magnetic Resonance Spectroscopy 4Erlotinib Hydrochloride 4130-nm albumin-bound paclitaxel 4cemiplimab 3atezolizumab 3anlotinib 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cobimetinib 2auricularum 2aumolertinib 2apatinib 2Vemurafenib 2Topotecan 2Temozolomide 2Surgical Procedures, Operative 2Standard of Care 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Cyclophosphamide × Thoracic × Clear all
NCT07463313 2026-03-11

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2/3 Not yet recruiting
116 enrolled
Thoracic

Thymic epithelial tumor, Mediastinal Neoplasms, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡